Target selection and clinical chimeric antigen receptor T cell activity against solid tumors
Abstract Chimeric antigen receptor (CAR) T cell therapy is a relatively new form of targeted therapy that has demonstrated impressive success in treating hematological malignancies. It has been challenging to translate this success to solid tumors. Reasons for this include barriers to delivery, tumo...
Saved in:
| Main Authors: | Eric vonHofe, Yanping Yang, Moonsoo M. Jin |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-06-01
|
| Series: | iLabmed |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/ila2.8 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The use of T-cells with chimeric antigen receptor (CAR-T) in combination with chemotherapy and radiotherapy for the treatment of solid tumors
by: M. R. Khaliulin, et al.
Published: (2024-04-01) -
Advancements and challenges in CAR-T cell therapy for solid tumors: A comprehensive review of antigen targets, strategies, and future directions
by: Jiajun Zhu, et al.
Published: (2025-08-01) -
Current challenges and emerging opportunities of chimeric antigen receptor-engineered cell immunotherapy
by: Yong Liu, et al.
Published: (2025-07-01) -
Precision sniper for solid tumors: CAR-NK cell therapy
by: Sisi Li, et al.
Published: (2025-07-01) -
Biomarkers for predicting efficacy of chimeric antigen receptor T cell therapy and their detection methods
by: Bo Zou, et al.
Published: (2024-03-01)